Microbiome / FMT

The scientific consensus underscores that the human gut microbiota functions analogously to a newly discovered organ, significantly influencing host health, metabolic homeostasis, and systemic disease [2]. Advanced 'omic' technologies reveal that gut microbiota dysbiosis contributes to the pathophysiology of diverse conditions, including cardiovascular diseases like hypertension [3], metabolic disorders such as type 2 diabetes [4], and neurodegenerative conditions like Alzheimer's disease via the microbiota-gut-brain axis [8, 9, 10]. Interventions aimed at modulating microbial composition—such as probiotics in very low birth weight preterm infants [1] and prebiotics or dietary adjustments to stimulate beneficial taxa like *Bifidobacteria* and butyrate-producing colon bacteria [5, 6]—demonstrate the clinical relevance of targeting the microbiome.

Open questions remain regarding the precise mechanistic pathways linking specific taxonomic groups to disease states, as human reports and taxonomic associations often vary [4]. Furthermore, while preclinical models strongly implicate the gut microbiota in bidirectional gut-brain interactions and metabolic dysfunction [3, 8], translating these findings into targeted diagnostics and therapeutics for complex multifactorial disorders like Alzheimer's disease and colorectal carcinoma requires further clinical validation [7, 9, 10].

The strength of evidence varies by domain. Robust clinical data and systematic reviews support the efficacy of probiotics in specific neonatal populations [1] and validate the broad associations between diet, lifestyle, and microbial metabolic activity [6]. Conversely, evidence mapping specific bacterial taxa to type 2 diabetes or detailing the causal cascades in neurodegeneration remains heterogeneous, necessitating more standardized human studies [4, 9, 10].